2024 World Conference on Lung Cancer (WCLC) - ePosters-EP.07E.06 Long-Term Outcomes of Resected EGFR-Mutated Lung Adenocarcinoma

Pdf Summary

The study conducted at Royal Victoria Hospital in Belfast explored the epidemiological characteristics and long-term outcomes of resected EGFR-mutated lung adenocarcinoma in a predominantly Caucasian UK cohort. The research was retrospective and included patients with EGFR-mutated non-small-cell lung cancer (NSCLC) who underwent tumor resection between 2013 and 2024. It compared outcomes with EGFR-negative patients from 2017-2018.<br /><br />Key findings revealed that EGFR-positive patients experienced longer overall survival and disease-free survival, especially when treated with adjuvant tyrosine kinase inhibitors (TKIs) compared to traditional chemotherapy or placebo. The data indicated that EGFR mutation was more prevalent in females and never-smokers, with significant improvements in cause-specific mortality (p=0.008) and overall survival (86.55 vs. 56.87 months, p=0.046) for EGFR-positive patients. Common EGFR mutations were identified in Exons 19 and 21, with mean survival times of 94, 87, 78, and 69 months for mutations in Exons 19, 21, 18, and 20, respectively.<br /><br />The study demonstrated that recurrence and time to recurrence were negative prognostic factors, yet the utilization of salvage TKI therapy in EGFR-positive patients mitigated these factors, contributing to improved survival outcomes. The demographics highlighted a lower mortality rate among the EGFR-positive group (12.88% vs. 22.73%, p=0.001).<br /><br />Statistical analyses, including Kaplan-Meier curves and Cox regression models, confirmed the prognostic significance of EGFR mutations and underscored the efficacy of TKI therapy. The findings align with global epidemiologic trends in EGFR-mutated lung cancer, providing valuable insights into treatment outcomes in non-Asian populations. The study thus emphasizes the importance of EGFR testing and targeted therapies in improving survival outcomes for lung adenocarcinoma patients.

Asset Subtitle

Tunde Oyebanji

Meta Tag

Speaker Tunde Oyebanji

Topic Early-Stage Non-small Cell Lung Cancer

Keywords

EGFR-mutated lung adenocarcinoma

Royal Victoria Hospital

Caucasian UK cohort

long-term outcomes

tyrosine kinase inhibitors

non-small-cell lung cancer

exon mutations

survival outcomes

Kaplan-Meier curves

Cox regression models